Login to Your Account



Financings Roundup

Alexza Raises $16M Ahead of AZ-004 NDA Resubmission

By Trista Morrison


Wednesday, May 4, 2011
Six months after receiving a surprise complete response letter from the FDA for agitation drug AZ-004 (Staccato loxapine), Alexza Pharmaceuticals Inc. padded its coffers before trying again.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription